Skymab Biotherapeutics has been selected among the 10 laureates of the Paris-Saclay Cancer Cluster (PSCC) BOOST Grant, a highly competitive program supporting breakthrough oncology innovations.
The award recognizes the potential of Skymab's next-generation ADC platform and will accelerate key translational, regulatory and partnering milestones toward clinical development.